(616 Kb) May 2026

Explain the specific (toxicities) that led to these discontinuations. Compare these results to more recent ibrutinib studies .

Toxicities and outcomes of 616 ibrutinib-treated patients in ... - PMC

The authors argue that because the drug is highly effective but often hard to tolerate, the medical community should focus on: (616 KB)

: Finding ways to help patients manage side effects so they can stay on the therapy longer.

The researchers analyzed a large group of 616 patients with who were treated with ibrutinib. The goal was to see if the high success rates found in clinical trials were mirrored in everyday medical practice across various hospitals. Key Findings and Statistics Explain the specific (toxicities) that led to these

: A major finding was that 41% of patients stopped taking ibrutinib within a median of 17 months.

: Patients in clinical trials were generally younger, with a mean age of 58 compared to 61 in this real-world group. - PMC The authors argue that because the

: Despite the high rate of stopping, the overall survival and progression-free survival (estimated at 35 months) remained excellent. Real-World vs. Clinical Trials